![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Retreatment with Telaprevir/Peg-IFN/RBV after a Short Exposure to Telaprevir in Phase I Studies: Interim Results from a Phase IIIb Rollover Trial (C219)
|
|
|
Reported by Jules Levin
AASLD SF Nov 5-9 2011
C Sarrazin,1 HW Reesink,2 S Zeuzem,1 CJ Weegink,2 D Luo,3 J Witek,3 TL Kieffer,4 D Bartels,4 I Dierynck,5 S De Meyer,5 G Picchio3
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam,
The Netherlands; 3Tibotec Inc., Titusville, NJ, USA; 4Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 5Tibotec BVBA, Beerse, Belgium
![AASLD1.gif](../images/110711/110711-9/AASLD1.gif)
![AASLD2.gif](../images/110711/110711-9/AASLD2.gif)
![AASLD3.gif](../images/110711/110711-9/AASLD3.gif)
![AASLD4.gif](../images/110711/110711-9/AASLD4.gif)
![AASLD5.gif](../images/110711/110711-9/AASLD5.gif)
![AASLD6.gif](../images/110711/110711-9/AASLD6.gif)
![AASLD7.gif](../images/110711/110711-9/AASLD7.gif)
![AASLD8.gif](../images/110711/110711-9/AASLD8.gif)
![AASLD9.gif](../images/110711/110711-9/AASLD9.gif)
![AASLD10.gif](../images/110711/110711-9/AASLD10.gif)
![AASLD11.gif](../images/110711/110711-9/AASLD11.gif)
![AASLD12.gif](../images/110711/110711-9/AASLD12.gif)
![AASLD13.gif](../images/110711/110711-9/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|